Clinical research
On the back of the two positive Phase III trials, Ortho said it will submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.
Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.
Humanigen reported positive data from its Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL).
The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
A Phase II schizophrenia treatment is showing promise for patients diagnosed with this complex and chronic brain disorder.
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
PRESS RELEASES